Alzheimer's disease

News

Closeup of X-ray photography of human brain

Could Lilly’s donanemab readout in Alzheimer's boost Biogen’...

When Eli Lilly reported results for donanemab in Alzheimer’s disease earlier this week it was hailed as a rare win for the amyloid hypothesis, although there’s no shortage of candidates tha

News

FDA panel unimpressed with data for Alzheimer’s drug aducanu...

The FDA may have been minded to approve Biogen and Eisai’s Alzheimer’s candidate aducanumab, but its clinical advisors have little doubt that the evidence for the drug is lacking.<

News

Trials and tribulations in Biogen's Alzheimer’s drug reviews

Regulatory reviews of Biogen’s Alzheimer’s drug aducanumab are now ongoing on both sides of the Atlantic, but debate is still ongoing about whether the data behind the drug is strong enough

News

AC Immune poleaxed on Alzheimer’s study fail

Shares in AC Immune have collapsed after partner Genentech revealed its tau-targeting Alzheimer’s drug semorinemab had flunked a phase 2 trial in Alzheimer’s disease (AD). The Swis

News

Concept of memory loss and brain aging due to dementia and alzheimer's disease as a medical icon with fall trees shaped as a human head losing leaves with 3D illustration elements.

Roche doubles down on tau for Alzheimer’s, licensing UCB dru...

Roche already has one Alzheimer’s candidate in its pipeline targeting tau, but has added a second via a deal with Belgian drugmaker UCB worth up to $2 billion.

Views & Analysis